<?xml version="1.0" encoding="UTF-8"?>
<p>The importance of additional human herpes viruses (HHV6 and 7) has been debated in recent years. According to some series, HHV6-infected patients have higher rates of acute and chronic allograft rejection, bacterial and opportunistic infections, a higher risk for CMV disease, and shorter graft survival [
 <xref ref-type="bibr" rid="CR85">85</xref>]. While HHV6 reactivation is common after solid organ transplantation, clinical disease is rare, manifesting as fever, myelosuppression, and end organ disease including encephalitis and hepatitis. Treatment is indicated for end organ disease and includes foscarnet, ganciclovir, and cidofovir [
 <xref ref-type="bibr" rid="CR86">86</xref>].
</p>
